Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Cipla
Accenture
Moodys
Argus Health
Medtronic
Chubb
Covington

Generated: November 20, 2018

DrugPatentWatch Database Preview

Bristol Myers Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS, and when can generic versions of BRISTOL MYERS drugs launch?

BRISTOL MYERS has eighty-two approved drugs.

There are seventeen US patents protecting BRISTOL MYERS drugs.

Summary for Bristol Myers

Drugs and US Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 AB RX Yes Yes ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb REMSED promethazine hydrochloride TABLET;ORAL 083176-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb DROXIA hydroxyurea CAPSULE;ORAL 016295-002 Feb 25, 1998 RX Yes No ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb ETHRIL 500 erythromycin stearate TABLET;ORAL 061605-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-004 May 30, 2008 AB RX Yes Yes 6,596,746*PED ➤ Sign Up Y ➤ Sign Up
Bristol Myers Squibb COUMADIN warfarin sodium TABLET;ORAL 009218-018 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Bristol Myers

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-005 Oct 9, 1991 5,254,539*PED ➤ Sign Up
Bristol Myers Squibb PRAVACHOL pravastatin sodium TABLET;ORAL 019898-004 Mar 22, 1993 5,622,985*PED ➤ Sign Up
Bristol Myers Squibb PRAVACHOL pravastatin sodium TABLET;ORAL 019898-002 Oct 31, 1991 5,622,985*PED ➤ Sign Up
Bristol Myers Squibb PRAVACHOL pravastatin sodium TABLET;ORAL 019898-003 Oct 31, 1991 5,622,985*PED ➤ Sign Up
Bristol Myers Squibb VIDEX didanosine FOR SOLUTION;ORAL 020155-003 Oct 9, 1991 5,616,566*PED ➤ Sign Up
Bristol Myers Squibb BUSPAR buspirone hydrochloride TABLET;ORAL 018731-002 Sep 29, 1986 4,182,763*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BRISTOL MYERS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16

Supplementary Protection Certificates for Bristol Myers Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00357 Netherlands ➤ Sign Up PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
2017000039 Germany ➤ Sign Up PRODUCT NAME: SULIQUA (FIRMENEIGENER NAME DES MEDIZINISCHEN PRODUKTS) BZW. WIRKSTOFFZUSAMMENSETZUNG UMFASSEND INSULIN GLARGIN / LIXISENATID UND IHRE PHARMAZEUTISCH ANNEHMBAREN SALZE (INTERNATIONALER, NICHT FIRMENEIGENER NAME); REGISTRATION NO/DATE: EU/1/16/1157 20170111
0736 Netherlands ➤ Sign Up PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119
2017000040 Germany ➤ Sign Up PRODUCT NAME: SCHNELL-WIRKENDES INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
13/034 Ireland ➤ Sign Up APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001
0900210/01 Switzerland ➤ Sign Up PRODUCT NAME: ATAZANAVIR; REGISTRATION NUMBER/DATE: SWISSMEDIC 56288 06.05.2004
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Moodys
Deloitte
UBS
Harvard Business School
Medtronic
Daiichi Sankyo
Farmers Insurance
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.